• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
LI Jing,MENG Di,YANG Lu,YANG Shu.Clinical study of Thalidomide combined with CIK cells on the treatment of lymphoma[J].Journal Of Pharmaceutical Research,2015,34(12):734-736[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 4375times   Download 3726次 QR Code for this article
Scan with your phone!
沙利度胺联合CIK细胞治疗淋巴瘤的临床研究
李静,孟迪,杨璐,杨舒
Font:Larger+|Default|Smaller-
(枣庄矿业集团中心医院,山东 枣庄 277800)
摘要:
目的 评价沙利度胺联合自体细胞因子诱导的杀伤细胞(CIK)治疗B细胞淋巴瘤的有效性和安全性。方法 选择2011年1月至2014年1月住院治疗的淋巴瘤患者64例,随机分为观察组(32例)和对照组(32例),观察组采用沙利度胺联合自体细胞因子诱导的杀伤细胞治疗,对照组采用单纯自体细胞因子诱导的杀伤细胞治疗,比较两组治疗效果及不良反应,随访观察生存情况。结果 治疗后观察组和对照组患者均未出现不良反应,β2微球蛋白、乳酸脱氢酶值均显著下降(P<0.05),观察组下降的更明显(P<0.05)。所有患者均症状改善,生活质量显著提高,观察组总有效率84.3%,对照组总有效率60%(P<0.05);观察组1年无进展生存率82.3%,对照组1年无进展生存率为62.7%(P<0.05);观察组1年总生存率为96.8%,对照组1年总生存率为77.4%(P<0.05)。结论沙利度胺联合自体细胞因子诱导的杀伤细胞治疗B细胞淋巴瘤较单纯自体CIK细胞治疗更能有效提高患者缓解率,延长患者生存期,且无明显毒副作用,值得进一步研究。
关键词:  沙利度胺  细胞因子诱导杀伤细胞  淋巴瘤
DOI:10.13506/j.cnki.jpr.2015.12.015
基金项目:
Clinical study of Thalidomide combined with CIK cells on the treatment of lymphoma
LI Jing,MENG Di,YANG Lu,YANG Shu
(Central Hospital Of Zaozhuang Mining Group,Zaozhuang 277800,China)
Abstract:
Objective To evaluate the effectiveness and security of cytokine-induced killer cells' cure on B-cell lymphoma.Methods 64 cases of lymphoma patients in hospital from Jan.2010 to Jan.2013 were selected and divided into observation group (32 patients) and control group (32 patients) randomly.The observation group was treated by Thalidomide combined with CIK cells,while the control group by CIK cells.The treatment effects,adverse reactions of two groups were recorded and compared.Results Adverse reaction was not occurred in two groups. The levels of beta-2-microglobulin and LDH were reduced remarkably,especially in the observation group.Clinical symptoms and living quality of all the patients in both groups were improved.The total effective rates of observation group and control group were 84.3%,60%(P<0.05),respectively.The PFS rates of observation group and control group in one year were 82.3%,62.7%(P<0.05),respectively. The total survival rates of observation group and control group in one year were 96.8%,77.4%(P<0.05),respectively.Conclusion Compared with CIK cells,Thalidomide showed a better performance in improving patient remission rate,extending patient survival without obvious toxic and side effects to be worth for a further research.
Key words:  Thalidomide  Cytokine-induced killer cells  Lymphama
Today's Visits:446    Total Visits:2383130
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.